Tourbillon Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tourbillon Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-147,193	Closed	-$14.3M	–	4
2018 Q3	$14.3M	Sell	147,193 -90,000	-38%	-$8.98M	1.54%	24
2018 Q2	$22.3M	Buy	+237,193	New	+$20.8M	0.86%	38
2016 Q2	–	Sell	-85,000	Closed	-$7.01M	–	64
2016 Q1	$7.01M	Buy	+85,000	New	+$6.92M	0.15%	54
2015 Q1	–	Sell	-415,000	Closed	-$37.5M	–	80
2014 Q4	$37.5M	Sell	415,000 -85,000	-17%	-$7.07M	1.01%	37
2014 Q3	$36.1M	Buy	+500,000	New	+$32.9M	1.32%	24

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tourbillon Capital Partners's BMRN Position: Q4 2018 in Review

Tourbillon Capital Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2018, closing a stake of 147,193 shares — an estimated $14.3M sold.

Tourbillon Capital Partners first reported a position in BMRN in Q3 2014 and held it in 5 quarters. The position peaked at $37.5M in Q4 2014. 473 funds tracked by Wall St. Rank hold BMRN as of Q4 2018.

Tourbillon Capital Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Tourbillon Capital Partners sold 147,193 BioMarin Pharmaceuticals shares in Q4 2018, an estimated $14.3M.
Tourbillon Capital Partners first reported a position in BioMarin Pharmaceuticals in Q3 2014 and held it in 5 quarters.
Tourbillon Capital Partners's BioMarin Pharmaceuticals position peaked at $37.5M in Q4 2014.
473 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2018.

Based on Tourbillon Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.